Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.36 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6803134 | 0.98 | EPHX1 (0.42) | MEN1KMT2AGAAHCRTR2EPHX1 | |
| SCHEMBL21930398 | 0.97 | MEN1 (0.41) | MEN1KMT2AGAAHCRTR2EPHX1 | |
| SCHEMBL335137 | 0.93 | TDP1 (0.46) | MEN1KMT2AGAAHCRTR2EPHX1 | |
| SCHEMBL1970278 | 0.86 | HCRTR2 (0.44) | MEN1KMT2AGAAHCRTR2EPHX1 | |
| SCHEMBL7439320 | 0.86 | MEN1 (0.39) | MEN1KMT2AGAAHCRTR2EPHX1 | |
| SCHEMBL101043 | 0.85 | CYP4F2 (0.44) | MEN1KMT2AGAAHCRTR2EPHX1 | |
| SCHEMBL20980198 | 0.85 | EPHX1 (0.42) | MEN1KMT2AGAAHCRTR2EPHX1 | |
| SCHEMBL25226121 | 0.85 | MEN1 (0.42) | MEN1KMT2AGAAEPHX1CYP2C19 | |
| SCHEMBL6630529 | 0.84 | MEN1 (0.46) | MEN1KMT2AGAAEPHX1TDP1 | |
| SCHEMBL27995921 | 0.84 | EPHX1 (0.41) | MEN1KMT2AGAAHCRTR2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD (US) | 2025-10-30 | — | — | US | disclosed |
| US-12295942-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-05-13 | — | — | US | disclosed |
| US-12213965-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-02-04 | — | — | US | disclosed |
| US-12005047-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-12005046-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2024-03-21 | — | — | US | disclosed |
| US-11911369-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-02-27 | — | — | US | disclosed |
| US-20200085794-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD. (JP) | 2020-03-19 | — | — | US | disclosed |
| WO-2019189876-A1 | (CARBOXYLIC ACID-TYPE COMPOUND)-POLYMER CONJUGATE HAVING BIOLOGICAL ACTIVITY, AND METHOD FOR PRODUCING SAME | 生化学工業株式会社 | 2019-10-03 | — | — | WO | disclosed |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| EP-3265448-A1 | RILUZOLE PRODRUGS AND THEIR USE | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2018-01-10 | — | — | EP | disclosed |
| CN-107567438-A | Riluzole prodrug and application thereof | 拜尔哈文制药股份有限公司 | 2018-01-09 | — | — | CN | disclosed |
| WO-2016140879-A9 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016140878-A9 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-8835461-B2 | Substituted 3-hydroxy-4-pyridone derivative | SHIONOGI & CO., LTD. (JP) | 2014-09-16 | — | — | US | disclosed |
| US-20020128185-A1 | Pharmaceutical compounds | HAWAII, UNIVERSITY OF | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | MEN1 1667/4885KMT2A 2213/4885GAA 510/4885 |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | MEN1 3255/4885KMT2A 3288/4885GAA 2244/4885 |
| US-12005046-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | MEN1 1667/4885KMT2A 2213/4885GAA 510/4885 |
| US-11911369-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | MEN1 1952/4885KMT2A 2513/4885GAA 541/4885 |
| US-20020128185-A1 | Pharmaceutical compounds | XPO5, XPOT, XPO1 | MEN1 45/4885KMT2A 3754/4885GAA 806/4885 |
| US-12005047-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | MEN1 1667/4885KMT2A 2213/4885GAA 510/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | MEN1 3290/4885KMT2A 3363/4885GAA 2222/4885 |
| US-12472165-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | MEN1 1667/4885KMT2A 2213/4885GAA 510/4885 |
| US-12295942-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | MEN1 1667/4885KMT2A 2213/4885GAA 510/4885 |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | APEH, CYP2C9, ALDH1A2 | MEN1 1865/4885KMT2A 2693/4885GAA 471/4885 |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | MEN1 1952/4885KMT2A 2513/4885GAA 541/4885 |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | MEN1 1667/4885KMT2A 2213/4885GAA 510/4885 |
| US-20200085794-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | MEN1 1667/4885KMT2A 2213/4885GAA 510/4885 |
| US-12213965-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | MEN1 1667/4885KMT2A 2213/4885GAA 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.